

INTERMOLECULAR INC
Form 8-K
May 11, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 09, 2018

Intermolecular, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

3011 N. First Street

San Jose, California
(Address of Principal Executive Offices)

001-35348 20-1616267
(Commission (IRS Employer

File Number) Identification No.)

95134
(Zip Code)

Edgar Filing: INTERMOLECULAR INC - Form 8-K

(408) 582-5700

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

On May 09, 2018, Mr. Bruce M. McWilliams, chairman and a director of the board of directors (the “Board”) of Intermolecular, Inc. (the “Company”), notified the Company that he would resign from the Board, effective immediately. Mr. McWilliams has served as a director of the Company since March 2005 and his decision to resign did not involve any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

On May 11, 2018, the board of directors appointed Kenneth H. Traub as chairman of the board and decreased the number of authorized directors from nine to eight. Mr. Traub has been a member of the Board since June 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERMOLECULAR,
INC.

Date: May 11, 2018 By: /s/ Bill Roeschlein
Bill Roeschlein
Chief Financial Officer